Connect with us


Global Contrast Media Strategic Business Report 2023: Growing Preference for Non-Ionizing Radiation-Based Radioimaging Drives Demand for Contrast Enhanced MRI

Global Contrast Media Strategic Business Report 2023: Growing Preference for Non-Ionizing Radiation-Based Radioimaging Drives Demand for Contrast Enhanced MRI
PR Newswire
DUBLIN, March 29, 2023

DUBLIN, March 29, 2023 /PRNewswire/ — The “Contrast M…



Global Contrast Media Strategic Business Report 2023: Growing Preference for Non-Ionizing Radiation-Based Radioimaging Drives Demand for Contrast Enhanced MRI

PR Newswire

DUBLIN, March 29, 2023 /PRNewswire/ -- The "Contrast Media: Global Strategic Business Report" report has been added to's offering.

Global Contrast Media Market to Reach $6.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Contrast Media estimated at US$4.9 Billion in the year 2022, is projected to reach a revised size of US$6.2 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2022-2030.

X-ray/Computed Tomography (CT), one of the segments analyzed in the report, is projected to record a 1.8% CAGR and reach US$2.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Magnetic Resonance Imaging (mri) segment is readjusted to a revised 3.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 4.5% CAGR

The Contrast Media market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$409.3 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.6% and 2.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$343.3 Million by the year 2030.

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel.

Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year.

Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New for 2023?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Key Topics Covered:


  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Prevalence of Chronic Diseases Among the Growing Global Population Pushes Up the Diagnostic Burden & Demand for Imaging
  • Rising Prevalence of Chronic Diseases Amplifies the Volume of Imaging Procedures, Driving Opportunities for Imaging Agents
  • The US$ 37 Billion Robustly Growing Medical Imaging Market Provides Lucrative Opportunities for Contrast Agents for Advanced Visualization
  • Aging Population, a Demographic Catalyst Driving Demand for Imaging Services
  • Rapidly Aging Population & the Challenges Associated With Geriatric Imaging Spurs Demand for Contrast Imaging Agents
  • Rise of Nuclear Medicine, the Cornerstone for the Growth for Radioactive Tracers
  • Improving Quality & Value of Nuclear Medicine Bodes Well for Radioactive Contrast Agents
  • Short Supply of Technetium-99m Threatens to Impact Nuclear Imaging Services
  • Plagued by the Risk of Reactor Decommissioning & Unplanned Maintenance Shutdowns, Fragile Supply of Mo-99 Will Remain a Cause for Concern
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)


  • Migration to Value Based Care Throws the Focus on Quality & Value of Imaging & Its Ability to Improve Patient Care by Providing Better Quality Images
  • With "Value" being the new Currency in Healthcare Markets Worldwide, Value Based Imaging Will Positively Impact Contrast Enhanced Imaging Procedure
  • Growing Preference for Non-Ionizing Radiation-Based Radioimaging Drives Demand for Contrast Enhanced MRI
  • Commercially Available MRI Contrast Agents
  • Spurred by Safety & Efficiency Benefits, Growing MRI Procedures & Parallel Increase in MRI Machines to Benefit Demand for MRI Contrast Agents
  • Equipment Density Correlates With Number of Imaging Procedures
  • Evolving Clinical Applications of Contrast-Enhanced Ultrasound (CEUS) Drive Demand for Ultrasound Contrast Agents
  • Clinically Available Ultrasound Contrast Agents
  • Growing Use of CEUS in Emergency and Critical Care
  • Special Focus on Microbubble Contrast Agents for Ultrasound Imaging
  • Clinical Applications of Microbubbles
  • Oscillating Microbubbles: To Revolutionize Ultrasound
  • Growing Market for Ultrasound Equipment Pushes Up the Number of CEUS Procedures Performed
  • Continued Value of CT Imaging in Cardiology Despite Risk of Radiation Exposure Drives Demand for Contrast-Enhanced CT
  • Contrast Agents Used in CT Imaging by Class: A Snapshot
  • CCTA Gaining Traction in Coronary Arteries Imaging
  • List of Iodine-Containing Contrast Agents for Coronary CT Angiography
  • Growing Access to CT Imaging Bodes Well for CT Contrast Agents
  • Rise in Image Guided Surgeries Drives Demand for Contrast Agents
  • Emergence of Molecular-Targeted Fluorescent Tracers
  • Select Potential "always-on" Targeted Tracers for Fluorescence Image-Guided Surgery (FIGS)
  • The Use of Gold Nanoclusters as Contrast Agent for IGS of Head and Neck Tumors
  • Better Surgical Outcome Drives the Number of Image Guided Surgeries Performed Worldwide Along with Demand for Contrast Agents
  • Stringent Guidelines & Implementation of Best Practices for Safe Use of Contrast Agents to Encourage Patient Acceptance of Contrast Enhanced Imaging
  • Safety Issues with Iodinated Agents, Gadolinium BCA and Microbubbles
  • Symptoms of Reaction to Administration of Iodinated Contrast Media Agents
  • Innovations Remain Crucial to Growth
  • A Review of Advancements in Contrast Media Injector Technology
  • Development of New Contrast Agents
  • Key Challenges Confront the Market
  • Advances in Imaging Technology Reduce Contrast Media Use
  • Product Recalls and Side Effects of Contrast Media Challenge Growth
  • A Snapshot of Side Effects, Allergic and Adverse Reactions with Contrast Agents


  • AMAG Pharmaceuticals, Inc. (USA)
  • Bayer Healthcare LLC (USA)
  • Bracco Imaging SpA (Italy)
  • GE Healthcare (USA)
  • Genovis AB (Sweden)
  • Guerbet Group (France)
  • J.B. Chemicals & Pharmaceuticals Ltd. (India)
  • Jodas Expoim (India)
  • Lantheus Medical Imaging, Inc. (USA)
  • Magnus Health (India)
  • Medtronic Plc. (Ireland)
  • nanoPET Pharma GmbH (Germany)
  • Sanochemia Pharmazeutika AG (Austria)
  • Spago Nanomedical AB (Sweden)
  • Taejoon Pharm Co., Ltd. (South Korea)
  • Unijules Life Sciences Ltd. (India)

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


View original content:

SOURCE Research and Markets

Read More

Continue Reading


Caroline Ellison wanted to step down but feared a bank run on FTX

Former Alameda CEO Caroline Ellison recognized she wasn’t doing a good job months before the company filed for bankruptcy, but Sam Bankman-Fried persuaded…



Former Alameda CEO Caroline Ellison recognized she wasn’t doing a good job months before the company filed for bankruptcy, but Sam Bankman-Fried persuaded her to stay.

Caroline Ellison wasn’t doing a good job leading Alameda Research in 2022, and she did not hide it. Excerpts from her personal notes shared as evidence by prosecutors in Sam Bankman-Fried’s trial revealed details about the trading firm’s struggles and its CEO’s desire to resign weeks and months before FTX collapsed.

Ellison spent over 10 hours testifying during Bankman-Fried’s trial this past week, notably entering through the front doors of the United States District Court for the Southern District of New York in Manhattan, joined by her attorneys. Ellison said she had not seen Bankman-Fried since the crypto empire failed in November 2022, but their communication had eroded months before.

In April 2022, their romantic relationship ended, and Caroline started avoiding meetings with Bankman-Fried even though they still lived in the same luxurious apartment in the Bahamas. Alameda’s growing liabilities with FTX and the breakup with Bankman-Fried made her consider leaving the company altogether.

“I feel like neither [Sam] Trabucco nor I have been doing a great job of pushing on stuff,” she wrote in the document to Bankman-Fried, which was shared as evidence during her cross-examination by the former FTX CEO’s defense counsel.

Bankman-Fried asked her to stay on, saying that her departure could create rumors about Alameda’s financial health, thus harming FTX’s credibility, so Ellison remained CEO.

Ellison joined Alameda as a trader in 2018. By 2020, she handled most of the company’s operations, while Bankman-Fried focused on his newly launched crypto exchange, FTX. In August 2021, she became co-CEO alongside Sam Trabucco, who stepped down a few months later, leaving her in charge of the company. In August 2022, Trabucco officially resigned as co-CEO.

Ellison was against creating FTX, she revealed. “I didn’t think of myself as ambitious before I started at Alameda, but I believe I became more ambitious” under Bankman-Fried’s incentive, she said.

As CEO, Ellison was in charge of handling Alameda’s crypto lenders. In mid-2022, after the Terra ecosystem failed, the company’s open-term loans stood at $1.3 billion. The market downturn drained liquidity from crypto assets, prompting Alameda’s lenders to demand loan repayments.

According to Ellison, Bankman-Fried instructed her to keep repaying creditors via Alameda’s line of credit with FTX. In other words, Alameda would use FTX’s customer assets to repay crypto lenders. At the time, its line of credit with the exchange stood at $13 billion.

As lenders demanded loan repayments and Alameda’s balance sheets, Bankman-Fried suggested Ellison use “alternative means” for presenting the company’s financials. In the following months, Ellison would create many additional versions of a balance sheet to deceive creditors.

Early in November 2022, an alternative version of Alameda’s balance sheet was leaked. Ellison was on vacation in Japan at the time, but she had to travel to FTX Hong Kong’s office to deal with the company’s crisis.

While the balance sheet data didn’t reflect the company’s reality, it was enough to spread rumors and trigger a bank run on FTX a few days later, exposing an $8 billion gap between the companies.

Having cooperated with the U.S. Department of Justice since December 2022, Ellison will soon receive her sentence regarding the seven counts of fraud and conspiracy to commit fraud she was charged with.

Magazine: Blockchain detectives — Mt. Gox collapse saw birth of Chainalysis

Read More

Continue Reading


ProShares prepares to launch unique Short Ether Strategy ETF

ProShares’ SETH ETF will start trading soon, following the first Ethereum futures ETFs by about two weeks.
ProShares introduced a trio…



ProShares' SETH ETF will start trading soon, following the first Ethereum futures ETFs by about two weeks.

ProShares introduced a trio of Ethereum futures ETFs in the recent weeks. Presently, the company is gearing up to provide a distinctive offering.

ProShares' Short Ether Strategy ETF (SETH) from the fund group is poised to commence trading shortly, following the debut of the initial Ethereum futures ETFs by about two weeks.

SETH, scheduled for listing on the NYSE Arca exchange, aims to achieve daily investment outcomes that mirror the inverse of the daily S&P CME Ether Futures Index performance, as indicated in a filing made on Friday, Oct. 13.

The fund does not engage in direct shorting of ether (ETH); rather, it seeks to capitalize on potential declines in the asset's value, as stated in the prospectus. On Friday, the price of ETH stood at approximately $1,540, reflecting a decrease of approximately 6% over the past week.

Screenshot of the ProShares SETH filing     Source: SEC

ProShares anticipates that the registration statement for SETH will become effective on Oct. 15 and plans to introduce the fund in early November, as reported by Blockworks.

However, the three existing ProShares ether futures funds — including two that invest in both ether and bitcoin futures contracts — debuted on Oct. 2 alongside similar products by VanEck and Bitwise.

The US Securities and Exchange Commission approved ether futures ETFs two years following the introduction of the initial bitcoin futures ETF, the ProShares Bitcoin Strategy ETF (BITO), which entered the market in Oct. 2021.

Related: SEC reportedly won’t appeal court decision on Grayscale Bitcoin ETF

ProShares continued its release of bitcoin futures ETFs with the Short Bitcoin Strategy ETF (BITI) in June 2022. As of now, BITO has accumulated around $850 million in assets, while BITI has approximately $75 million.

In August, Cointelegraph reported that Ether futures ETFs may be approved in October, causing an 11% spike in ETH prices at the time.

Magazine: Bitcoin ETF optimist and Worldcoin skeptic Gracy Chen: Hall of Flame

Read More

Continue Reading


SEC reportedly won’t appeal court decision on Grayscale Bitcoin ETF

If true, the SEC will need to review and decide on Grayscale’s spot Bitcoin ETF application. If denied, Grayscale could appeal the decision.



If true, the SEC will need to review and decide on Grayscale’s spot Bitcoin ETF application. If denied, Grayscale could appeal the decision.

The United States Securities and Exchange Commission reportedly has no plans to appeal the recent court decision that favored Grayscale Investments. The ruling requires the SEC to review the firm’s spot Bitcoin (BTC) exchange-traded fund (ETF) application.

The SEC’s supposed decision not to appeal the D.C. Circuit Court of Appeal’s ruling was highlighted in an Oct. 13 report from Reuters, which cited “a source familiar with the matter.”

Bloomberg analysts also expect the SEC not to appeal to the Supreme Court but emphasized that this doesn’t necessarily mean Grayscale’s application is set to be approved.

If the reports are true, the SEC will need to follow the court’s August order and review Grayscale’s application to change its Grayscale Bitcoin Trust (GBTC) into a spot Bitcoin ETF.

According to Reuters, the appeals court is expected to issue a mandate specifically outlining how its ruling should be “executed” by the SEC.

Commenting on the developments, Bloomberg ETF analyst James Seyffart noted via X that:

“I do not think they will appeal to the Supreme Court either. Dialogue between Grayscale and SEC should begin next week. Hoping for more info on next steps sometime next week or week after?”

Moving forward, Seyffart suggested that it is likely that “we will find out in the next week (or two)” what the deadline is for the SEC to approve or deny Grayscale’s spot BTC ETF application.

If the SEC were to deny the application, Grayscale could then appeal that decision, dragging the process out even longer.

Related: Bitcoin price gets new $25K target as SEC decision day boosts GBTC

As it stands, around seven spot Bitcoin ETF applications have been put before the SEC that are awaiting a decision from the regulator.

In a separate preceding X post on Oct. 13, Seyffart reiterated his view that there is a 90% chance that a spot Bitcoin ETF application will get approved in January 2024, specifically the application from Cathie Wood’s ARK Invest.

Seyffart and Bloomberg’s senior ETF analyst Eric Balchunas, also previously suggested that there is a 75% chance that an application will get approved in 2023.

Magazine: Hall of Flame: Crypto lawyer Irina Heaver on death threats, lawsuit predictions

Read More

Continue Reading